AUB ScholarWorks

In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon

Show simple item record

dc.contributor.author Araj G.F.
dc.contributor.author Jaber F.A.
dc.contributor.editor
dc.date 2012
dc.date.accessioned 2017-10-05T15:59:35Z
dc.date.available 2017-10-05T15:59:35Z
dc.date.issued 2012
dc.identifier
dc.identifier.isbn
dc.identifier.issn 00239852
dc.identifier.uri http://hdl.handle.net/10938/19101
dc.description.abstract BACKGROUND: The incidence of urinary tract infections (UTIs) caused by extended-spectrum-β-lactamase (ESBL) producing Escherichia coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP) has been on the rise limiting oral treatment options. Fosfomycin was reported to be highly efficacious against these organisms, however, data is lacking in Lebanon and the Middle East. OBJECTIVE: To determine the in vitro activity of fosfomycin against ESBL and non-ESBL-producing E. coli and K. pneumoniae uropathogens in Lebanon. METHODS: A total of 542 consecutive non-duplicate isolates of ESBL-producing E. coli (n = 374) and K. pneumoniae (n = 168), and 291 isolates of non-ESBL-producing E. coli (n = 236) and K. pneumoniae (n = 55) were recovered from urine specimens of patients tested at the American University of Beirut Medical Center (AUBMC) during 2010. Each isolate was tested against a battery of 13 antimicrobials by disk diffusion according to the guidelines of CLSI testing and result interpretation criteria. RESULTS : The fosfomycin susceptibility for ESBL-producing vs. non-ESBL-producing isolates was 86percent vs. 97percent for E. coli and 62percent vs. 78percent for K. pneumoniae. This activity of fosfomycin among ESBL-EC and ESBL-KP was generally higher than cefepime (26percent and 30percent), ciprofloxacin (24percent and 41percent), Trimeth-sulfa (26percent and 19percent), Pip-taz (75percent and 45percent), gentamicin (45percent and 42percent), and tobramycin (32percent and 26percent). On the other hand, higher activity against both species of ESBL-producing bacteria was shown by amikacin (96percent and 79percent) and imipenem (99.7percent and 98.8percent). Nitroflurantoin was highly active against ESBL-EC (95percent) but not against ESBL-KP (29percent). CONCLUSION: Fosfomycin shows good activity, being higher against ESBL-producing E. coli than K. pneumoniae uropathogens in Lebanon.
dc.format.extent
dc.format.extent Pages: (142-147)
dc.language English
dc.relation.ispartof Publication Name: Journal Medical Libanais; Publication Year: 2012; Volume: 60; no. 3; Pages: (142-147);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon
dc.type Article
dc.contributor.affiliation Araj, G.F., Dept. Pathology and Laboratory Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Beirut 1107-2020, Lebanon
dc.contributor.affiliation Jaber, F.A., Dept. Pathology and Laboratory Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Beirut 1107-2020, Lebanon
dc.contributor.authorAddress Araj, G.F.; Dept. Pathology and Laboratory Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Beirut 1107-2020, Lebanon; email: garaj@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Pathology and Laboratory Medicine;
dc.contributor.authorDepartment Pathology and Laboratory Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited
dc.description.citedCount 5
dc.description.citedTotWOSCount
dc.description.citedWOSCount
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden LMJJA
dc.identifier.pubmedID 23198454
dc.identifier.scopusID 84870353382
dc.identifier.url
dc.publisher.address
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr
dc.relation.ispartOfIssue 3
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal Medical Libanais
dc.relation.ispartofPubTitleAbbr J. Med. Liban.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 60
dc.source.ID
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS amikacin, 37517-28-5, 39831-55-5
dc.subject.otherChemCAS aztreonam, 78110-38-0
dc.subject.otherChemCAS cefepime, 88040-23-7
dc.subject.otherChemCAS cefotaxime, 63527-52-6, 64485-93-4
dc.subject.otherChemCAS ceftazidime, 72558-82-8
dc.subject.otherChemCAS ciprofloxacin, 85721-33-1
dc.subject.otherChemCAS cotrimoxazole, 8064-90-2
dc.subject.otherChemCAS fosfomycin, 23155-02-4
dc.subject.otherChemCAS gentamicin, 1392-48-9, 1403-66-3, 1405-41-0
dc.subject.otherChemCAS imipenem, 64221-86-9
dc.subject.otherChemCAS nitrofurantoin, 54-87-5, 67-20-9
dc.subject.otherChemCAS tobramycin, 32986-56-4
dc.subject.otherChemCAS Anti-Bacterial Agents
dc.subject.otherChemCAS Fosfomycin, 23155-02-4
dc.subject.otherIndex amikacin
dc.subject.otherIndex aztreonam
dc.subject.otherIndex cefepime
dc.subject.otherIndex cefotaxime
dc.subject.otherIndex ceftazidime
dc.subject.otherIndex ciprofloxacin
dc.subject.otherIndex cotrimoxazole
dc.subject.otherIndex extended spectrum beta lactamase
dc.subject.otherIndex fosfomycin
dc.subject.otherIndex gentamicin
dc.subject.otherIndex imipenem
dc.subject.otherIndex nitrofurantoin
dc.subject.otherIndex piperacillin plus tazobactam
dc.subject.otherIndex tobramycin
dc.subject.otherIndex adult
dc.subject.otherIndex antibacterial activity
dc.subject.otherIndex antibiotic sensitivity
dc.subject.otherIndex article
dc.subject.otherIndex bacterium isolate
dc.subject.otherIndex controlled study
dc.subject.otherIndex disk diffusion
dc.subject.otherIndex extended spectrum beta lactamase producing Enterobacteriaceae
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex in vitro study
dc.subject.otherIndex Klebsiella pneumoniae
dc.subject.otherIndex Lebanon
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex nonhuman
dc.subject.otherIndex tertiary health care
dc.subject.otherIndex urinalysis
dc.subject.otherIndex uropathogenic Escherichia coli
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Anti-Bacterial Agents
dc.subject.otherIndex Escherichia coli Infections
dc.subject.otherIndex Female
dc.subject.otherIndex Fosfomycin
dc.subject.otherIndex Humans
dc.subject.otherIndex Klebsiella Infections
dc.subject.otherIndex Klebsiella pneumoniae
dc.subject.otherIndex Lebanon
dc.subject.otherIndex Male
dc.subject.otherIndex Microbial Sensitivity Tests
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Tertiary Care Centers
dc.subject.otherIndex Urinary Tract Infections
dc.subject.otherIndex Uropathogenic Escherichia coli
dc.subject.otherKeywordPlus
dc.subject.otherWOS


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account